Technology | 2017.09.12
Aethlon Medical Receives Expedited Access Pathway Designation from FDA to Accelerate U.S. Access to the Hemopurifier® as a Treatment for Life-Threatening Viruses
SAN DIEGO, Sept. 12, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that it has received an Expedited Access Pathway (EAP) designation from the United States Food and Drug...
For more information, please visit
http://www.prnewswire.com/news-releases/[...]atening-viruses-300517683.html
